BioXcel Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioXcel Therapeutics, Inc. (BTAI) is a clinical-stage biopharmaceutical company leveraging artificial intelligence to develop therapeutics for neuroscience and immuno-oncology. The company focuses on repurposing approved drugs and developing de novo small molecule product candidates; its neuroscience pipeline includes BXCL501, an oral film formulation of dexmedetomidine for agitation in schizophrenia and bipolar disorder, and BXCL502, a next-generation serotonin 2A receptor agonist for neuropsychiatric disorders; its immuno-oncology pipeline features BXCL701, an oral dipeptidyl peptidase 9 inhibitor for combination therapy in solid and liquid tumors. BioXcel Therapeutics operates primarily in the United States, with headquarters in New Haven, Connecticut, founded in 2017 as a subsidiary of BioXcel Corporation. Recent major developments include the completion of Phase 3 TRANQUILITY trials for BXCL501 in 2024, positive topline results from the Phase 2b SERENITY trial demonstrating significant reductions in agitation, and ongoing preparations for a New Drug Application submission to the FDA; the company also reported advancements in its immuno-oncology programs, including Phase 2 data for BXCL701 in pancreatic cancer combinations, alongside strategic financing rounds to support pipeline progression amid a challenging biotech funding environment.
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
BioXcel Therapeutics Preps IGALMI At-Home Launch Ahead of Nov. 14 FDA Label Decision
BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting Transcript
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia
Short Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Increases By 32.6%